Show simple item record

dc.contributor.authorJessica Price, Jessica Mooney, Carolyn Bain, John Tanko Bawa, Nikki Gurley, Amresh Kumar, Guwani Liyanage, Rouden Esau Mkisi, Chris Odero, Karim Seck, Evan Simpson, William P Hausdorff
dc.date.accessioned2022-06-29T15:59:20Z
dc.date.available2022-06-29T15:59:20Z
dc.date.issued2022-01-21
dc.identifier.urihttps://repository.maseno.ac.ke/handle/123456789/5309
dc.description.abstractCurrently available live, oral rotavirus vaccines (LORVs) have significantly reduced severe rotavirus hospitalizations and deaths worldwide. However, LORVs are not as effective in low- and middle-income countries (LMIC) where rotavirus disease burden is highest. Next-generation rotavirus vaccine (NGRV) candidates in development may have a greater public health impact where they are needed most. The feasibility and acceptability of possible new rotavirus vaccines were explored as part of a larger public health value proposition for injectable NGRVs in LMICs.en_US
dc.publisherElsevieren_US
dc.subjectRotavirusRotavirus vaccines Next-generation rotavirus vaccines Value proposition New vaccine introduction Vaccine decision-makingen_US
dc.titleNational stakeholder preferences for next-generation rotavirus vaccines: Results from a six-country studyen_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record